About Novavax
Novavax is a company based in Gaithersburg (United States) founded in 1987.. The company has 952 employees as of December 31, 2024. Novavax has completed 2 acquisitions, including Isconova and PRAHA VACCINES. Novavax offers products and services including Matrix-M Adjuvant and Recombinant Nanoparticle Vaccine Technology. Novavax operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter Gaithersburg, United States
- Employees 952 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Novavax, Inc.
-
Annual Revenue
$682.16 M-30.65as on Dec 31, 2024
-
Net Profit
$-187.5 M65.6as on Dec 31, 2024
-
EBITDA
$-183.47 M50.92as on Dec 31, 2024
-
Latest Funding Round
$84.5 M (USD), Post-IPO
Sep 08, 2023
-
Investors
NIH
& 11 more
-
Employee Count
952
as on Dec 31, 2024
-
Investments & Acquisitions
Isconova
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Novavax
Novavax is a publicly listed company on the NASDAQ with ticker symbol NVAX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Novavax
Novavax offers a comprehensive portfolio of products and services, including Matrix-M Adjuvant and Recombinant Nanoparticle Vaccine Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enhances immune response in vaccines for infectious diseases
Develops protein-based vaccines for global health protection
Unlock access to complete
Unlock access to complete
Leadership Team
93 people
Software Development Team
55 people
Senior Team
22 people
Operations Team
22 people
Product Management Team
17 people
Finance and Accounting
16 people
Legal and Compliance
11 people
Scientist Team
7 people
Unlock access to complete
Funding Insights of Novavax
- Total Funding Total Funding
- Total Rounds 15
- Last Round Post-IPO — $84.5M
-
First Round
First Round
(04 Feb 2005)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Post-IPO - Novavax | Valuation |
investors |
|
| Jul, 2020 | Amount | Grant - Novavax | Valuation |
investors |
|
| Jun, 2020 | Amount | Post-IPO - Novavax | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Novavax
Novavax has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Gates Foundation and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by this private equity firm.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Innovative vaccines are developed and manufactured by SK bioscience.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Novavax
Novavax has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Isconova and PRAHA VACCINES. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Serums and vaccines are developed and produced by PRAHA VACCINES.
|
2017 | ||||
|
Vaccine adjuvants are developed for infectious diseases and veterinary applications.
|
1999 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Novavax
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Novavax Comparisons
Competitors of Novavax
Novavax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
|
| domain | founded_year | HQ Location |
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Novavax
Frequently Asked Questions about Novavax
When was Novavax founded?
Novavax was founded in 1987 and raised its 1st funding round 18 years after it was founded.
Where is Novavax located?
Novavax is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Who is the current CEO of Novavax?
John Jacobs is the current CEO of Novavax.
How many employees does Novavax have?
As of Dec 31, 2024, the latest employee count at Novavax is 952.
What is the annual revenue of Novavax?
Annual revenue of Novavax is $682.16M as on Dec 31, 2024.
What does Novavax do?
Novavax was founded in 1987 and is headquartered in Gaithersburg, United States. Vaccines are developed by the company in the biotechnology sector, focusing on recombinant nanoparticle platforms and adjuvant technology. The pipeline encompasses candidates for respiratory syncytial virus, coronavirus, malaria, Ebola, and seasonal quadrivalent influenza. Operations center on advancing these vaccine technologies for global health needs.
Who are the top competitors of Novavax?
Novavax's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
What products or services does Novavax offer?
Novavax offers Matrix-M Adjuvant and Recombinant Nanoparticle Vaccine Technology.
Is Novavax publicly traded?
Yes, Novavax is publicly traded on NASDAQ under the ticker symbol NVAX.
How many acquisitions has Novavax made?
Novavax has made 2 acquisitions, including Isconova, and PRAHA VACCINES.
Who are Novavax's investors?
Novavax has 12 investors. Key investors include NIH, Gates Foundation, HHS, Path, and RA Capital.
What is Novavax's ticker symbol?
The ticker symbol of Novavax is NVAX on NASDAQ.